A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma

PURPOSE: NF-κB, a transcription factor essential for inflammatory responses, is constitutively activated in many lymphomas. In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-κB signaling and demonstrated antitumor activity in vitro. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, Kristie A., Supko, Jeffrey G., Maris, Michael B., Flinn, Ian W., Goy, Andre, Younes, Anas, Bobba, Suresh, Senderowicz, Adrian M., Efuni, Sergey, Rippley, Ronda, Colak, Gozde, Trojer, Patrick, Abramson, Jeremy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010313/
https://www.ncbi.nlm.nih.gov/pubmed/36923307
http://dx.doi.org/10.1158/2767-9764.CRC-22-0060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010313/
https://www.ncbi.nlm.nih.gov/pubmed/36923307
http://dx.doi.org/10.1158/2767-9764.CRC-22-0060

Ejemplares similares